Researchers Submit Patent Application, "Transdermal Delivery Formulations", for Approval (USPTO 20240390264).

The patent application by Joel M. Friedman focuses on a transdermal delivery formulation for therapeutic agents targeting diseases associated with elevated CD38 levels and decreased NAD+ levels. The formulation aims to enhance NAD+ levels, promote sirtuin activity, and reduce inflammation by targeting CD38 overproduction. The application discusses the potential benefits of the formulation in treating various conditions, including cardiovascular diseases, inflammatory conditions, and age-related decline in physical and cognitive function. The formulation includes curcuminoids, senolytic flavonoids, polyols, and fatty acids for transdermal delivery, bypassing the gut and liver for effective administration. [Extracted from the article]